2019 Oncofertility Conference: Optimizing Outcomes in Fertility and Reproductive Health
https://cancer.osu.edu/events/2019-oncofertility-conference-05-18-19 401 N. High St., Columbus, Ohio 43215 false DD/MM/YYYY
Hilton Columbus Downtown
401 N. High St.
Columbus Ohio 43215
This conference is intended for physicians, nurses and other healthcare providers who treat children, adolescents and young adults with cancer before, during and after treatment: oncologists, obstetricians and gynecologists; urologists, reproductive endocrinologists and infertility specialists; primary care physicians, pediatricians, pediatric and adult endocrinologists, psychologists, social workers; and oncofertility researchers.
Early Registration - Conference Attendee = $100
Ohio State/Nationwide Children's Faculty/Staff = $50
Students/Fellows = $0
Early Bird Registration
An early registration rate of $100 will be available through Monday, April 15. On Tuesday, April 16, the registration fee will increase to $125.
Discounted Registration Rate Available to Poster Presenters (Primary Authors)
Abstract submissions for poster presentations are currently being accepted. If your abstract is accepted, you will be extended a discounted registration rate of $50 to attend the conference.
If you plan to submit an abstract, please wait to register for the conference. The abstract submission deadline is March 15, and you will be notified of abstract acceptance by April 1. If your poster is not accepted, you will still have approximately two weeks to take advantage of the early registration rate.
Use this link to book your group rate at the Hilton Columbus Downtown. Be sure to select your arrival and departure dates for the room rate.
Questions? Contact Sarah Schmidt at Sarah.Schmidt@osumc.edu.
This conference is made possible in part by the generous funding provided by NextGen. NextGen is a subgroup of The James Ambassadors Society, the premier advocacy group for the OSUCCC – James. NextGen is a group that develops, connects and empowers young professionals aged 21-39 who have an affinity to end cancer.